In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19

Set Alert for COVID-19

Clinical Trials: Have We Finally Reached The New Normal?

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.

Clinical Trials Outlook 2023

Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing

Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, explains how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.

Commercial Coronavirus COVID-19

Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times

How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.

Commercial Business Strategies

As COVID-19 Successes Fuel R&D, Efforts Focus On mRNA Optimization

In the third part of this special focus on mRNA manufacturing, In Vivo looks at the many directions mRNA platforms can expand, with a major focus on optimizing cellular microenvironments for safety and efficacy.

Vaccines Manufacturing

Challenges And Opportunities As mRNA Manufacturing Spreads Its Wings Beyond COVID-19 Vaccines

In the second part of In Vivo's series on mRNA manufacturing, we look at the technology behind the Moderna and Pfizer/BioNTech COVID-19 vaccines. Experts in the field are working on a variety of improvements that will enable quicker, cheaper, surer development and production of what could turn out to be a wide array of vaccines and therapeutics to be churned out by emerging mRNA platforms.

Supply Chain Manufacturing

Inflation, Supply Chain Headaches And Staffing Shortages: CEOs Talk About 'Big Picture' Challenges

Although procedure volumes have mostly recovered from the shock of COVID-19 two years ago, the effects of the pandemic on the medtech sector and the economy overall will be felt for years to come. In recent analyst and sales and earnings presentations, CEOs of major medtech companies faced questions about how their company is handling these major "macro" issues.

Leadership Sales & Earnings

The Emergence Of A New Medicinal Platform: mRNA

In the first of a three-part series on the evolution of mRNA manufacturing, this article looks back to before the pandemic, when dogged mRNA researchers and entrepreneurs labored in obscurity pursuing the dream of revolutionizing healthcare by commandeering the body’s own protein building process to generate quicker, cheaper vaccines and therapeutics. Then the mRNA COVID-19 vaccines stunned the world.

Manufacturing Coronavirus COVID-19

Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication

Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.

FDA Advertising, Marketing & Sales

The Buck Stops Here: BD CEO Tom Polen On How To Make A Medtech Company Succeed

BD CEO Tom Polen is at the bottom of the pyramid – it’s where he wants to be and is best positioned to continue the company’s transition to focusing on high-growth spaces, as set out in the BD2025 strategy.

Leadership Medical Device

Funding The Future: Accelerating The Long Walk To Innovation

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

New Science StartUps and SMEs

CEO Snapshots From The MedTech Forum

Among the highlights of MedTech Europe’s annual MedTech Forum are the “unfiltered” views offered by company CEOs on the entire range of issues that influence decision-making or will have an impact on business operations in the near term.

Leadership Medical Device

Compassionate Use Programs In APAC: China Breaks The Ice

Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities. 

Market Access Asia Pacific

2021 Global Biopharma R&D Productivity And Growth Ranking

A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.

Growth Research & Development

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Market Intelligence Diversity & Inclusion

How To Improve Diversity And Inclusion: Five Companies Share Best Practices

Company strategies at improving diversity, equity and inclusion both within their organizations and in the clinical trials they conduct have differed, but building trust is a common theme.

Coronavirus COVID-19 Diversity & Inclusion

How COVID-19 Disrupted The Clinical Trial Status Quo

As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects COVID-19 has brought. For the biopharmaceutical industry, clinical trials have been at the forefront.

Clinical Trials Coronavirus COVID-19
See All
UsernamePublicRestriction

Register